Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 10.39M P/E - EPS this Y 11.40% Ern Qtrly Grth -
Income -18.35M Forward P/E -0.63 EPS next Y 5.00% 50D Avg Chg -5.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -7.00%
Dividend N/A Price/Book 0.22 EPS next 5Y - 52W High Chg -64.00%
Recommedations 2.00 Quick Ratio 3.73 Shares Outstanding 17.15M 52W Low Chg 76.00%
Insider Own 1.93% ROA -21.73% Shares Float 16.82M Beta 1.47
Inst Own 6.14% ROE -38.93% Shares Shorted/Prior 394.78K/362.57K Price 0.69
Gross Margin - Profit Margin - Avg. Volume 749,319 Target Price -
Oper. Margin - Earnings Date May 9 Volume 127,579 Change 5.68%
About Theriva Biologics, Inc.

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Theriva Biologics, Inc. News
04/25/24 Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
04/23/24 Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma
04/22/24 Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
04/08/24 Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
03/26/24 Theriva Biologics, Inc. (NYSE:TOVX) Q4 2023 Earnings Call Transcript
03/25/24 Q4 2023 Theriva Biologics Inc Earnings Call
03/25/24 Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
03/19/24 Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results
03/11/24 Theriva™ Biologics to Participate in the BIO-Europe Spring Conference
02/07/24 Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
01/16/24 Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference
12/05/23 Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now
11/20/23 Theriva Biologics, Inc. (NYSE:TOVX) Q3 2023 Earnings Call Transcript
11/14/23 Q3 2023 Theriva Biologics Inc Earnings Call
11/13/23 Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results
11/06/23 Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results
11/02/23 Theriva™ Biologics to Participate in the BIO-Europe Conference
11/02/23 Theriva™ Biologics and Sant Joan de Déu-Barcelona Children’s Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer
06:00 AM Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register Now
10/23/23 Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023
TOVX Chatroom

User Image Yupppp Posted - 6 hours ago

$TOVX frozen on here....

User Image jtrades90 Posted - 12 hours ago

$TOVX why isn’t stocktwits working

User Image BearRifle Posted - 04/30/24

$TOVX We need to lock this up. It would be easy. We need some influencers to care about curing pancreatic cancer and making $$$ in the process

User Image Yupppp Posted - 04/30/24

$TOVX

User Image ZACHSPIZZA Posted - 04/30/24

$TOVX let’s get some volume back this week

User Image BearRifle Posted - 04/30/24

$TOVX

User Image kcma Posted - 04/29/24

$TOVX

User Image jtrades90 Posted - 04/29/24

$TOVX

User Image Yupppp Posted - 04/29/24

$TOVX

User Image Papamidnight155 Posted - 04/29/24

$TOVX 🇺🇸

User Image ZACHSPIZZA Posted - 04/29/24

$TOVX

User Image chucksters Posted - 04/29/24

$TOVX

User Image Aidan001 Posted - 04/29/24

$TOVX

User Image jtrades90 Posted - 04/29/24

$TOVX

User Image ZACHSPIZZA Posted - 04/29/24

$TOVX

User Image exwallstcfo Posted - 04/26/24

$TOVX So what happened in the past week ??? ..... only that the MMs were successful in scaring the amateurs to selling at a major low .... Common sense prevailed .... you dont sell with good news being accumulated at a fast rate !!! It's been a year since I added at 33/35c .... what a bargain .... dont want to add to much hype ... but I believe steady progress is in the works this year

User Image jtrades90 Posted - 04/26/24

$TOVX good start

User Image ZACHSPIZZA Posted - 04/26/24

$TOVX 50k already to the buy side let’s gooo

User Image ZACHSPIZZA Posted - 04/26/24

$TOVX .50 today LFG

User Image Papamidnight155 Posted - 04/26/24

$TOVX https://www.globenewswire.com/news-release/2024/04/25/2869618/0/en/Theriva-Biologics-to-Discuss-the-Trial-Design-for-VIRAGE-a-Phase-2b-Clinical-Study-of-Systemically-Administered-VCN-01-in-Combination-with-Chemotherapy-in-Pancreatic-Ductal-Adenoca.html

User Image BearRifle Posted - 04/25/24

$TOVX Someone please make an insider documentary on what's happening with this stock. Hey hedgies if you're listening, please take good notes for the tell all. This thing could go to $15-75/sh if it's adding months to pancreatic cancer victim's lives, and if they start adding years to lives with VCN-01, well, wen mooooon.

User Image Bubbagreg2024 Posted - 04/25/24

$TOVX Nice reversal bar at close!

User Image Aidan001 Posted - 04/25/24

$TOVX Wow

User Image jtrades90 Posted - 04/25/24

$TOVX big push to end let’s go

User Image ZACHSPIZZA Posted - 04/25/24

$TOVX break .41 and run

User Image ZACHSPIZZA Posted - 04/25/24

$TOVX just added another 5k in increments

User Image ZACHSPIZZA Posted - 04/25/24

$TOVX get back to .50 then I’ll be impressed

User Image Olweis Posted - 04/25/24

$TOVX Let's go!!

User Image asdflkj Posted - 04/25/24

$TOVX news?

User Image ZACHSPIZZA Posted - 04/25/24

$TOVX @exwallstcfo you add yet?

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
SHALLCROSS STEVEN A CEO and CFO CEO and CFO Jun 07 Buy 0.6931 14,000 9,703 250,000 06/08/23
SHALLCROSS STEVEN A CEO and CFO CEO and CFO Jun 06 Buy 0.6328 26,000 16,453 236,000 06/07/23
SHALLCROSS STEVEN A CEO and CFO CEO and CFO Feb 10 Buy 1.043 25,000 26,075 210,000 02/13/23
SHALLCROSS STEVEN A CEO and CFO CEO and CFO Feb 02 Buy 0.9405 25,000 23,512 185,000 02/03/23
SHALLCROSS STEVEN A CEO and CFO CEO and CFO Jan 25 Buy 0.873 25,000 21,825 160,000 01/26/23
SHALLCROSS STEVEN A CEO and CFO CEO and CFO Jan 20 Buy 0.7482 25,000 18,705 135,000 01/23/23
SHALLCROSS STEVEN A CEO and CFO CEO and CFO Dec 29 Buy 0.437 100,000 43,700 110,000 01/03/23